2022 Fiscal Year Final Research Report
The Role of CARDS Toxin from Mycoplasma pneumoniae in Pathogenesis and Vaccine Development
| Project/Area Number |
21K20718
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0801:Pharmaceutical sciences and related fields
|
|---|
| Research Institution | Wakayama Medical University (2022)
Osaka University (2021) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-08-30 – 2023-03-31
|
| Keywords | Mycoplasma pneumoniae / 肺炎 / CARDS toxin / ワクチン |
|---|
| Outline of Final Research Achievements |
In the present study, we found that CARDS toxin, an exotoxin derived from Mycoplasma pneumoniae (Mycoplasma), not only induces pneumonia as an inflammatory factor but also contributes to adhesion of Mycoplasma to epithelial cells as an adhesion factor. In addition, our results suggest that CARDS toxin is useful as a novel vaccine antigen that can inhibit both infection and inflammation.
|
| Free Research Field |
細菌学、免疫学、ワクチン学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、マイコプラズマ感染時におけるCARDS toxinの新規機能を明らかとしており、今後のマイコプラズマ研究の礎になると思われる。また今後、新たな薬剤耐性マイコプラズマの出現が示唆されており、さらに治療薬の選択が困難になると予想される。そのため、感染そのものを予防するワクチンの開発が待望されているものの、未だその開発には至っていない。本研究は、新規治療薬・ワクチン開発に向けた基盤情報となり得ると期待される。
|
